Related Experiment Video
Updated: Aug 19, 2026

Non-invasive Imaging of Leukocyte Homing and Migration in vivo
Published on: December 6, 2010
Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan)
W Becker1, C J Palestro, J Winship
1Department of Nuclear Medicine of the University of Erlangen-Nuremberg, Germany.
Abstract:
The diagnostic accuracy for imaging infection with a technetium-99m-labeled antigranulocyte Fab' fragment (LeukoScan) was prospectively examined in a multicenter study. Scintigraphy was performed in 53 patients at 1 to 6 hours and at 24 hours after injection of the labeled antibody fragment. Thirty-nine sites of infection were detected and confirmed by histologic study, cytologic study, other imaging procedures, or by followup. Thirty-eight of the 53 patients also were studied with technetium-99m-Exametazim or indium-111-oxine labeled leukocytes within 1 week of the LeukoScan study. In 21 patients with 25 osteomyelitic lesions, LeukoScan recognized 13 of the lesions as being true positive ones, 10 as being true negative ones, and 2 as being false negative ones, whereas the leukocyte scan showed 9 true positive results, 5 true negative results, and 2 false negative ones. Sensitivity specificity, and diagnostic accuracy of LeukoScan were 90.0 %, 84.6 %, and 87.9 %; and with autologous leukocyte scintigraphy were 83.9%, 76.5%, and 81.3%, respectively. The sensitivity of LeukoScan was independent of the amount of the labeled antibody injected (0.1 - < 0.5 mg, 96.2%; 0.5 - < 0.9 mg, 80.0%; 0.9 - 1.0 mg, 77.8%). False positive lesions were detected in a periprosthetic calcification, a frontal hyperostosis, and 2 periprosthetic hips that had loosened. Human antimouse antibody could not be detected in any of the 13 patients tested 1 or 3 months after injection. LeukoScan is suitable for imaging infectious lesions and may have diagnostic advantages compared with autologous leukocyte scintigraphy.
Insights
LeukoScan, a technetium-99m-labeled antigranulocyte antibody fragment, shows high diagnostic accuracy for imaging infection. This nuclear medicine technique offers potential advantages over traditional leukocyte scintigraphy for detecting infectious lesions.
Area of Science:
- Nuclear Medicine
- Diagnostic Imaging
- Immunoscintigraphy
Background:
- Accurate imaging of infection is crucial for timely diagnosis and treatment.
- Existing methods like leukocyte scintigraphy have limitations in sensitivity and specificity.
- Technetium-99m-labeled antigranulocyte Fab' fragment (LeukoScan) offers a novel approach for infection detection.
Purpose of the Study:
- To prospectively evaluate the diagnostic accuracy of LeukoScan for imaging infection in a multicenter study.
- To compare the performance of LeukoScan with autologous leukocyte scintigraphy.
- To assess the influence of antibody dose on LeukoScan sensitivity.
Main Methods:
- A multicenter study involving 53 patients undergoing LeukoScan scintigraphy at 1-6 and 24 hours post-injection.
- Comparison with histologic, cytologic, other imaging, or follow-up confirmation of 39 infection sites.
- Subgroup analysis comparing LeukoScan with technetium-99m-Exametazim or indium-111-oxine labeled leukocytes in 38 patients.
Main Results:
- LeukoScan demonstrated a sensitivity of 90.0%, specificity of 84.6%, and diagnostic accuracy of 87.9%.
- Leukocyte scintigraphy showed lower performance: 83.9% sensitivity, 76.5% specificity, and 81.3% accuracy.
- LeukoScan sensitivity was largely independent of injected antibody dose, while false positives were noted in non-infectious conditions.
Conclusions:
- LeukoScan is a suitable and effective tool for imaging infectious lesions.
- LeukoScan offers potential diagnostic advantages over autologous leukocyte scintigraphy.
- No significant human antimouse antibody response was detected post-injection.

